

CRITERIA FOR PRIOR AUTHORIZATION

Antipsychotic Medications – Safe Use for All Ages

PROVIDER GROUP Pharmacy

MANUAL GUIDELINES The following drugs (all strengths and dose forms) will require prior authorization as outlined in the criteria below:

Aripiprazole (Abilify®, Abilify Discmelt®, Abilify Maintenna®, Aristada®, Aristada Initio™, [Abilify MyCite®](#))
 Asenapine (Saphris®)
 Brexpiprazole (Rexulti®)
 Cariprazine (Vraylar®)
 Chlorpromazine
 Clozapine (Clozaril®, Fazaclo®, Versacloz®)
 Fluphenazine
 Haloperidol (Haldol®)
 Iloperidone (Fanapt®)
 Loxapine (Adasuve®, Loxitane®)
 Lurasidone (Latuda®)
 Olanzapine (Zyprexa®, Zyprexa Zydis®)

Olanzapine pamoate (Zyprexa Relprevv®)
 Olanzapine/Fluoxetine (Symbyax®)
 Paliperidone (Invega®)
 Paliperidone palmitate (Invega Sustenna®, Invega Trinza®)
 Perphenazine
 Pimozide (Orap®)
 Quetiapine (Seroquel®, Seroquel XR®)
 Risperidone (Perseris™, Risperdal®, Risperdal Consta®, Risperdal M-Tab®)
 Thioridazine
 Thiothixene
 Trifluoperazine
 Ziprasidone (Geodon®)

CRITERIA FOR PRIOR AUTHORIZATION FOR ANTIPSYCHOTICS:

- PROVIDER TYPE/DIAGNOSIS:
 - For children < 6 years of age:
 - Must be prescribed only by (ages < 4 years) or in consultation/collaboration with (ages 4 – < 6 years) a psychiatrist, neurologist, or developmental/behavioral pediatrician.
 - Child must have a diagnosis of mood disorder, psychotic disorder, Tic disorder (i.e. Tourette's disorder), Autism Spectrum Disorder, PTSD with associated severe agitation.
 - For children and adolescents ages 6 to < 18:
 - Child must have a diagnosis of mood disorder, psychotic disorder, Tic disorder (i.e. Tourette's disorder), Autism Spectrum Disorder, PTSD with associated severe agitation.
 - For patients ≥ 65 years of age (long-term care, non-dual eligibility group) (must meet one of the following):
 - Diagnosis of schizophrenia, schizoaffective, delusional disorder, unspecified psychotic disorders, Huntington's disease (G10), Tourette's syndrome (F95.2), bipolar disorder, adjunctive treatment of major depressive disorder or irritability associated with autistic disorder.
 - Dementia/major neurocognitive disorder for the treatment of agitation or psychosis when symptoms present a danger to self or others.
- MULTIPLE CONCURRENT USE:
 - For patients receiving multiple antipsychotics concurrently, prior authorization will be required for:
 - Patients < 18 years of age, when two or more antipsychotics used concurrently for greater than 90 days (includes oral and long-acting injectables)
 - Must be prescribed by or in consultation/collaboration with a psychiatrist, neurologist, developmental/behavioral pediatrician
 - Patients ages ≥ 18 years of age, when three or more antipsychotics used concurrently for greater than 60 days (includes oral and long-acting injectables)
 - Must be prescribed by or in consultation/collaboration with a psychiatrist
 - Patients ages ≥ 18 years of age, when two or more concurrent long-acting injectable antipsychotics for greater than 60 days
 - Prior authorization will require a written peer-to-peer consult with health plan psychiatrist, medical director, or pharmacy director for approval, followed by a verbal peer-to-peer, if unable to approve written request.

- DOSING LIMITS:
 - The antipsychotic dose must not exceed the dosing limit listed in Table 1. If the dosing limit is exceeded, prior authorization will be required.
 - Prior authorization will require a written peer-to-peer consult with health plan psychiatrist, medical director, or pharmacy director for approval, followed by a verbal peer-to-peer, if unable to approve written request.
 - Drugs listed in Table 1 as not approved for the specified age range will require an appeal.
- STEP THERAPY (APPLICABLE TO ALL AGES):
 - ABILIFY MYCITE® (MUST MEET ALL OF THE FOLLOWING):
 - Must meet FDA label requirements for approved use.
 - Documented tolerance to aripiprazole tablets
 - Approval period of 12 weeks
 - Not able to receive injections
 - Requires peer-to-peer review

LENGTH OF APPROVAL: 12 months

*A one-time 30 day override for this criteria requirement will be available to dispensing pharmacies through the Point-of-Sale PBM adjudication system.

RENEWAL CRITERIA:

- Attestation of attempted gathering of fasting plasma glucose, lipid screening, weight, height, and Abnormal Involuntary Movement Scale (AIMS) within the previous 12 months.
- Patient is stable and has been seen in the past year.

Note – General prescribing recommendations:

- Prescriber should attempt to gather fasting plasma glucose, lipid screening, weight, height and Abnormal Involuntary Movement Scale (AIMS) evaluation within the previous 12 months.
- Documentation of developmentally-appropriate, comprehensive psychiatric assessment should be completed by the prescriber and documented in the child's medical record.
- Patient assessment should include DSM-5 or most updated edition of DSM diagnosis, screening for parental psychopathology, evaluation of family functioning and gathering collateral information from community resources (e.g., School).

Non-psychopharmacological interventions (i.e. training parents or caregivers in evidence-based behavior management) should be initiated before (and maintained, if indicated, during) psychopharmacological treatment is initiated.

DRUG UTILIZATION REVIEW COMMITTEE CHAIR

PHARMACY PROGRAM MANAGER
DIVISION OF HEALTH CARE FINANCE
KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT

DATE

DATE

TABLE 1. ANTIPSYCHOTIC MEDICATION DOSING LIMITS

Drug	Maximum Daily Dose* < 6yrs	Max Daily Dose* 6 To < 10yrs	Max Daily Dose* 10 To < 16yrs	Max Daily Dose* ≥ 16 To Adults
Aripiprazole (Abilify®, Abilify Discmelt® Abilify MyCite®),	15mg	20mg	30mg	45mg
Aripiprazole (Abilify Maintenance®)	Not approved	Not approved	Not approved	400mg per 28 days
Aripiprazole lauroxil (Aristada®)	Not approved	Not approved	Not approved	882mg per 28 days or 1064 every 2 months
Aripiprazole lauroxil (Aristada Initio™)	Not approved	Not approved	Not approved	675 mg single dose
Asenapine (Saphris®)	Not approved	10mg	20mg	20mg
Brexipiprazole (Rexulti®)	Not approved	Not approved	Not approved	4mg
Cariprazine (Vraylar®)	Not approved	Not approved	Not approved	6mg
Chlorpromazine (oral)	40mg	200mg	800mg	1500mg
Clozapine (Clozaril®, Fazaclo®, Versacloz®)	Not approved	300mg	600mg	900mg
Fluphenazine (oral)	Not approved	5mg	10mg	60mg
Fluphenazine HCL and Decanoate (injection)	Not approved	Not approved	Not approved	100mg
Haloperidol (Haldol®)	6mg or 0.15mg/kg/day ("Lesser of")	6mg	15mg	60mg
Haloperidol Decanoate (Haldol® Decanoate)	Not approved	Not approved	Not approved	500mg per 21 days
Iloperidone (Fanapt®)	Not approved	12mg	24mg	24mg
Loxapine (Adasuve® , Loxitane®)	Not approved	30mg	60mg	250mg
Loxapine (Adasuve®)	Not approved	Not approved	Not approved	10mg
Lurasidone (Latuda®)	Not approved	80mg	120mg	160mg
Olanzapine (Zyprexa®, Zyprexa Zydis®)	Not approved	12.5mg	20mg	40mg
Olanzapine pamoate (Zyprexa Relprevv®)	Not approved	Not approved	Not approved	300mg per 14 days or 405 mg every 28 days
Olanzapine/Fluoxetine (Symbyax®)	Not approved	Not approved	12mg/50mg	18mg/75mg
Paliperidone (Invega®)	Not approved	6mg	12mg	12mg
Paliperidone palmitate (Invega Sustenna®)	Not approved	Not approved	Not approved	234mg per 21 days
Paliperidone palmitate (Invega Trinza®)	Not approved	Not approved	Not approved	819mg per 84 days
Perphenazine	Not approved	12mg	22mg	64mg
Pimozide (Orap®)	Not approved	6mg or 0.2mg/kg/day ("Lesser of")	10mg or 0.2mg/kg/day ("Lesser of")	20mg
Quetiapine (Seroquel®, Seroquel XR®)	Not approved	400mg	800mg	1200mg
Risperidone (Perseris™)	Not approved	Not approved	Not approved	120 mg per 28 days
Risperidone (Risperdal®, Risperdal M-Tab®)	1.5mg	4mg	6mg	16mg
Risperidone (Risperdal Consta®)	Not approved	Not approved	Not approved	50mg per 14 days
Thioridazine	Not approved	Not approved	Not approved	800mg
Thiothixene	Not approved	Not approved	15mg	60mg
Trifluoperazine	Not approved	15mg	40mg	40mg
Ziprasidone (Geodon®)	Not approved	80mg	160mg	240mg

* Daily dose unless specified